智翔金泰(688443.SH)：2025年度净亏损5.36亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) reported significant growth in revenue for the fiscal year 2025, with total operating revenue reaching 231 million yuan, marking a 666.65% increase compared to the previous year. However, the company still recorded a net loss of 536 million yuan, although this loss has narrowed by 32.74% year-on-year [1]. Financial Performance - The company achieved total operating revenue of 231 million yuan, representing a year-on-year growth of 666.65% [1]. - The operating profit showed a year-on-year loss reduction of 33.57% [1]. - The total profit also saw a year-on-year loss reduction of 32.74% [1]. - The net profit attributable to the parent company was a loss of 536 million yuan, which is a 32.74% reduction in loss compared to the previous year [1]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 579 million yuan, reflecting a 27.99% reduction in loss year-on-year [1]. Key Drivers - The significant revenue growth is primarily attributed to the expansion of the sales market for the company's first commercialized product, Saliqi monoclonal antibody injection (Jinlixi®), which has shown steady growth in sales revenue compared to the previous year [1]. - The revenue from the licensing and commercialization agreement for GR1803 injection has also positively impacted the company's net profit for the current period due to substantial licensing income [1].